Online inquiry

IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4116MR)

This product GTTS-WQ4116MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ICAM1 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000201.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3383
UniProt ID P05362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4116MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12525MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ12143MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ13235MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ13287MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ13466MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ7529MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ5590MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ15477MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-0107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW